US/UK/Canada

Share

Pick a time period -
Tags ( Active)

The subscription period in Spermosens’ rights issue of units begins today

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE   Today, 11 November 2024, is the first day of the subscription period in Spermosens AB:s (publ) (“Spermosens” or the “Company”) issue of a maximum of 283,607,120 units, corresponding to a maximum of 2,268,856,960 shares,

Spermosens publishes information memorandum due to upcoming rights issue of units

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE   The Board of Directors of Spermosens AB (publ) ("Spermosens" or the "Company") has, in connection with the Company's upcoming rights issue of units that was announced on 3 October 2024 (the "Rights Issue"), prepared an

Spermosens announces advancements in second-generation JUNO-Checked system

Spermosens AB ("Spermosens" or the "Company") is pleased to share additional information on the enhanced capabilities of its second-generation JUNO-Checked system, a significant advancement in male fertility diagnostics. JUNO-Checked is the first device that enables clinicians and researchers to measure sperm binding capacity - a critical parameter that complements current analyses in IVF clinics and provides deeper insights into male fertility.The second-generation JUNO-Checked system builds on the strengths of the initial platform, introducing enhancements in sensitivity, accuracy and

Announcement from the Extraordinary General Meeting of Spermosens AB (publ)

Spermosens AB ("Spermosens" or the "Company") held an Extraordinary General Meeting today, 4 November 2024. At the meeting, the shareholders approved all previously announced proposals. The decisions can be summarized as follows: The meeting resolved to reduce the share capital without cancelling shares, to cover losses, through an amendment of the Articles of Association and a decision to reduce the share capital. The new limits for the share capital are a minimum of SEK 560,000 and a maximum of SEK 2,240,000. The number of shares will be between 280,000,000 and 1,120,000,000.

Spermosens reduces spending by focusing on clinical study and business development

Spermosens AB ("Spermosens" or the "Company") is pleased to announce updates to its cost structure following the revised strategy. Over the past months, the Company has effectively adapted the organization to align with a new focus on the clinical study and business development, reducing overall spending and investment needs by more than 50%.As part of its strategic initiatives, Spermosens has concentrated resources on its clinical study and on building strategic partnerships for commercialization. With the introduction of the second-generation JUNO-Checked technology, the Company can now

Spermosens AB (publ)INTERIM REPORT JANUARY - SEPTEMBER 2024

Strong progress in clinical study1 JANUARY – 30 SEPTEMBER 2024 SIGNIFICANT EVENTS DURING THE QUARTER   · Spermosens next-generation male fertility diagnostic product ready for clinical study · Spermosens has entered into an agreement with US based ScanMed Partners to identify and attract strategic and commercial partners in North America with special focus on the US market · Spermosens passes an important milestone receiving approval for significant clinical study       SIGNIFICANT EVENTS AFTER THE END OF THE INTERIM PERIOD · Kallelse till extra bolagsstämma

Spermosens reports strong progress in clinical study

Spermosens AB ("Spermosens" or the "Company") is pleased to announce strong progress in its ongoing clinical study at Reproductive Medicine Center (RMC) in Malmö, where the Company is evaluating its innovative JUNO-Checked technology. The study, designed to demonstrate the diagnostic relevance of JUNO-Checked in addressing male infertility, is progressing ahead of expectations with a strong recruitment rate.The excellent collaboration between Spermosens and RMC has played a key role in exceeding recruitment goals, with couples now being enrolled at a faster pace than initially expected. The

Spermosens signs memorandum of understanding for commercial partnership in Japan

Spermosens AB ("Spermosens" or the "Company") is pleased to announce the signing of a Memorandum of Understanding (MoU) with a well established undisclosed Japanese company to explore a commercial partnership in Japan. This MoU lays the framework and intentions for discussions regarding the distribution and commercialization of Spermosens' fertility diagnostic product, JUNO-Checked, in Japan. Potential avenues include a licensing agreement or joint venture.JUNO-Checked is Spermosens' innovative and proprietary diagnostic product designed to assess male fertility. This solution is believed

Spermosens receives notice of allowance for broad US patent covering JUNO-Checked technology

Spermosens AB (publ) (“Spermosens” or the “Company”) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's second patent in the US, covering its innovative JUNO-Checked technology. The newly allowed patent, "Biosensor for Male Infertility" (Application no. 17/260,609), encompasses a broader range of claims compared to Spermosens' first US patent. This patent includes claims for a biosensor utilizing the JUNO protein immobilized on a variety of substrates, significantly expanding the scope beyond the previously

Spermosens recruits first couple for clinical study on next-generation male fertility diagnostic product

Spermosens AB (“Spermosens” or the “Company”) is pleased to announce a significant milestone in its clinical study of the next-generation fertility diagnostic product. The first couple has now been recruited for the study, which is designed to assess the diagnostic value of JUNO-Checked in male infertility. The clinical study, currently underway at the Reproductive Medicine Center (RMC) in Malmö, follows ethical approval for the study. Spermosens’ next-generation device, developed in collaboration with Flex Medical Solutions (FMS), features improved performance and faster read-out times,

Spermosens carries out a rights issue of units of approximately SEK 22.7 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE   Today, the board of directors in Spermosens AB (publ) (“Spermosens” or the “Company”) has, subject to approval by the extraordinary general meeting on 4 November 2024, resolved to carry out an issue of 283,607,120 units,

Spermosens next-generation male fertility diagnostic product ready for clinical study

Spermosens AB ("Spermosens" or the "Company") is pleased to announce the development of the next-generation of its JUNO-Checked device, a groundbreaking product designed to assess male fertility potential. Developed in collaboration with Flex Medical Solutions (FMS), this next-generation JUNO-Checked device will play a pivotal role in the upcoming clinical study, which has recently received ethical approval to be conducted at Reproductive Medicine Center (RMC) in Malmö. The new product generation offers enhanced performance, including faster read-out times, strengthening its ability to

Spermosens passes an important milestone receiving approval for significant clinical study.

Spermosens AB announces that the Swedish Ethical Review Authority has given approval for the company’s application to start a clinical study at Reproductive Medicine Center (RMC) in Malmö with JUNO-Checked to evaluate sperm quality for couples undergoing fertility treatment. This means that the company now takes the next step in validating diagnostic use of JUNO-Checked.Spermosens recently announced a revised strategy to accelerate the development and commercialisation of the unique JUNO-Checked product designed to address male infertility, with a clinical study conducted at RMC as a

Spermosens AB (publ) INTERIM REPORT JANUARY - JUNE 2024

The revised strategy positions Spermosens optimally to unlock the full potential of its groundbreaking product. Spermosens AB's interim report for the period January - June 2024, is now available on the Company's website and attached to this press release.1 JANUARY – 30 JUNE 2024 SIGNIFICANT EVENTS DURING THE QUARTER   · Spermosens receives patent approval in Singapore · The rights issue carried out during the month of April provided the company with SEK 24.2 million before issue costs, which amount to approximately SEK 7.0 million · Spermosens appoints Tore Duvold as new

Spermosens accelerates its US business development activities in collaboration with Scan MedPartners

Spermosens is accelerating its business development activities and has entered into an agreement with US based Scan MedPartners as its business development advisor to identify and attract potential strategic and commercial partners in North America with a special focus on the US market.As previously communicated, Spermosens is focused on securing licensing and co-development partners for its first of kind automated sperm diagnostic device JUNO-Checked. In line with this effort, Spermosens today announces a collaboration with Scan MedPartners, thereby significantly strengthening the company'

BioStock: Spermosens - helping couples succeed in babymaking

As infertility reaches an alarming rate, in vitro fertilisation is seen as a beacon of hope. Despite its successes, IVF too often leads to disappointment, so innovation in the field is in high demand. Spermosens is making significant strides to address these challenges with its diagnostic technology, JUNO-Checked. BioStock spoke with recently appointed CEO Tore Duvold to learn more about the company’s new strategy for bringing JUNO-Checked to the market.Read the full article at biostock.se : https://www.biostock.se/en/2024/07/spermosens-helping-couples-

Spermosens AB Announces Revised Strategy

Spermosens announce a revised strategy emphasizing an ambitious clinical study, commercial partnerships, and operational efficiency. Starting in Q3 2024, the company will initiate a clinical study at the Reproductive Medicine Center (RMC) in Malmö to demonstrate the diagnostic value of its unique JUNO-Checked product. Spermosens will intensify business development globally to identify the right commercial partners through license deals in key markets for its groundbreaking JUNO-Checked product, which has the potential to help couples struggling with infertility. The revised strategy

BioStock Investor Pitch: Spermosens

Swedish Spermosens’ vision is to improve diagnostics within the area of male infertility and thus help improve IVF treatments. Using the company’s JUNO-Checked system the sperm’s ability to bond to the egg cell can be tested and the result can help clinicians determine the best treatment course making IVF-treatments more efficient. CEO Ulrik Nilsson visited BioStock’s studio to present the company, its product, and the development plan.See the presentation at biostock.se: https://www.biostock.se/en/2023/01/biostock-investor-pitch-spermosens/ This is a press release from BioStock -

Spermosens has received grant from EU

As holder of Seal of Excellence in European Union's Horizon 2020, EU's prestigious program IPA4SME has once again awarded Spermosens the support for expansion and strengthening of its patent portfolio.The grant will reimburse up to 75% of the European Patent Office fees for European patent application (up to EUR 2 500), as well as 50% of the patent attorney fees for filing the Patent Application to the European Patent Office (up to EUR 2 000) until March 2022. “We are proud holders of the Seal of Excellence, and very grateful for once again being awarded support from EU´s prestigious

Spermosens patent granted by the European Patent Office

Spermosens AB today announces that the European Patent Office (EPO) has granted the patent EP 3 768 825, which protects the company’s biosensor and its use for in vitro fertilization. The formal grant follows the previous ”Intention to Grant”-notification communicated April 16[th] 2021.Based on EPO:s grant of the patent with number EP 3 768 825, a European protection exists until 2039 and encompasses the company’s biosensor product and its use for, e.g. detecting and quantifying sperm binding function, diagnosis of male infertility, and selection of sperms suitable for In Vitro

Spermosens appoints an Advisory Board

Spermosens AB (‘Spermosens’) announces today that the company is reinforcing its organization and appointing strategic leading to include industry experts in an Advisory Board.Following a need of assuring the continuous influx of clinical and scientific information in Spermosens’ products, the company is now pleased to introduce its newly appointed Advisory Board. Comprised of Spermosens’ management and scientific experts within the fields of IVF and fertility, the Advisory Board will bring relevant scientific and clinical aspects into discussion, bridging the company and the end users, by

Spermosens receives Intention to Grant from the European Patent Office

Spermosens AB today announces that the company has received an Intention to Grant from the European Patent Office (EPO) for its patent application directed to a biosensor and its use in In Vitro Fertilization (IVF). The next step in the process is a formal EPO approval, which provides a patent protection until 2039.The patent application, with application number no. 19759542.4, for which the EPO has issued an “Intention to Grant communication”, refers to the company’s biosensor product and its use for, e.g., detecting and quantifying sperm binding function, diagnosis of male infertility,

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe